Modest progress has been achieved over the past two decades in the treatment of adult acute lymphocytic leukemia (ALL). With modern therapy, response rates are 70% to 80%. but cure rates only average 25% to 30%. Improved in vivo models are needed t o investigate the biology of adult ALL and to test new treatment concepts. Fresh leukemia samples from children with ALL have been successfully transplanted into mice with severe combined immunodeficiency (SCID), but no experience exists for adult ALL. We treated SClD mice with 2 mg cyclophosphamide 24 hours before intravenously injecting 20 x 10' viable leukemia cells obtained from 13 patients with newly diagnosed adult ALL within five defined phenotype/karyotype subcategories. Ten (76%) of 13 injected leukemia specimens representing all five categories engrafted. The median survival duration of mice was 20 weeks from the time of leukemia cell injection. The rate of engraftment by ALL subset was as follows: two of two T-ESPITE INTENSIVE treatment regimens and marked improvement in supportive care, only 25% to 30% of adults with acute lymphocytic leukemia (ALL) can be cured.' Children with ALL have a much better prognosis, with a cure rate greater than 70%.* However, even in pediatric ALL, some cytogenetic categories carry a poor prognosis and a high risk of relap~e.~ Relapses in the majority of children with ALL are late, whereas adults frequently succumb to the disease within 1 year from diagnosis. This indicates that ALL is a heterogenous disease entity.
ESPITE INTENSIVE treatment regimens and marked improvement in supportive care, only 25% to 30% of adults with acute lymphocytic leukemia (ALL) can be cured.' Children with ALL have a much better prognosis, with a cure rate greater than 70%.* However, even in pediatric ALL, some cytogenetic categories carry a poor prognosis and a high risk of relap~e.~ Relapses in the majority of children with ALL are late, whereas adults frequently succumb to the disease within 1 year from diagnosis. This indicates that ALL is a heterogenous disease entity.
An animal model in which the biology of ALL could be investigated in vivo and new drugs tested would be valuable in the study of this complex disease and might improve our therapeutic strategies. Previous leukemic cell models have involved either animal leukemic cell lines or in vitro studies using human leukemic cell lines and fresh cells. Although some fresh human leukemic cells and established cell lines can grow in nude mice, they form localized solid tumors or ascites, a condition that does not reflect the normal course
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OOO6-4971/95/8611-0024$3.00/0 4278 cell, two of three t(llq23). two of two hyperdiploid, two of three t(9;22), and two of three diploid ALL. The pattern of organ involvement by leukemia in the mice was similar to that of the human disease. Immunohistochemistry and flow cytometry documented the stability of each leukemic phenotype after passage through SCID mice. Cells transplanted from the spleen and bone marrow of mice engrafted with ALL into recipient mice resulted in consistent engraftment. The survival duration in passage groups was similar to that in groups injected with primary cells. The high frequency of engraftment, availability of frozen original specimens, and successful passages in SClD mice provide an in vivo model of adult ALL suitable for further studies of the disease biology and for design of drug studies for the different subtypes of previously untreated adult ALL. 0 1995 by The American Society of Hematology.
of the disease in humans?' Recently, fresh leukemia cells from children with ALL have been successfully transplanted into severe combined immunodeficiency (SCID) but no information is available about adult ALL. In this investigation, we report the results of a study in which primary ALL cells with defined phenotype and karyotype, derived from untreated adult patients, engrafted in SCID mice preconditioned with cyclophosphamide but not treated with growth factors. This is the first human leukemic model in SCID mice to be reported for adult ALL.
PATIENTS AND METHODS
Patient materials, SClD mice, and transplantation procedure. We chose for investigation leukemic blast cells from 13 previously untreated adults who had ALL with selected phenotypic or cytogenetic abnormalities known to be associated with response to treatment and prognosis. Characteristics of the patients and leukemic cells are detailed in Table 1 . Leukemic cells were collected from the peripheral blood by leukapheresis at initial presentation. After separating mononuclear cells, including blast cells, by means of Ficoll-Hypaque (51,077 g/pL; Pharmacia Biotech US), cells were resuspended in freezing medium (20% fetal calf serum and 10% dimethyl sulfoxide in phosphate-buffered saline [PBS], pH 7.2) and frozen by a controlled-rate freezer (1"Clmin) to -80°C. They were then stored in liquid nitrogen until used. After thawing, the cells were resuspended in PBS with 5% fetal calf serum, and viability was assessed by the Trypan-blue exclusion test. All samples contained over 90% viable blast cells.
Leukemic cells were injected into 6-to 8-week-old female CB17-SCIDlSCID mice obtained from a commercial breeder (Taconic, Germantown, NY). The mice were kept in a pathogen-free environment in the animal facility of The University of Texas M.D. Anderson Cancer Center. They were housed in microisolator cages containing autoclaved bedding, food, and water with no added antibiotics. Leukemia cells (20 X IOh viable blasts in 0.1 mL PBS) were injected intravenously into the tail vein of mice conditioned 24 hours previously by intraperitoneal injection of cyclophosphamide (100 mglkg). The animals were monitored, and were killed when they became moribund or at completion of the study, 7 to 8 months after transplantation. In selected cases, leukemia cells were flushed from bone marrow and spleen of the mice and reinjected into untreated SCID mice for second-passage studies. No growth factors were administered. Histopathologic and immunohistochemical analysis of SCID mouse tissue. Tissues were fixed in 10% neutral buffered Formalin and embedded in paraffin. Sections were cut 3 to 4 pm thick and stained with hematoxylin and eosin. Immunohistochemical studies were performed on Formalin-fixed, paraffin-embedded tissue sections using the avidin-biotin-peroxidase complex method." Sections were deparaffinized in xylene and rehydrated in descending grades (100% to 70%) of ethanol. Endogenous peroxidase activity was blocked by a IO-minute treatment with 3% hydrogen peroxide in absolute methanol. Sections were then incubated with the primary antibodies overnight in a humid chamber at 4°C. The primary antibodies used were mouse monoclonal antibodies (MoAbs) to leukocyte-common antigen (LCA) (CD45, 1:40 dilution; Dako Corp, Carpinteria, CA), L26 (CD20, 1:100; Dako), UCHL-l (CD45R0, 1:20; Dako), polyclonal antibodies to lysozyme raised in rabbits (1:2,OOO; Dako), and terminal deoxynucleotidyltransferase ([Tdt] 1:100; SuperTechs, Bethesda, MD). To minimize background staining, sections were preincubated with normal horse serum for MoAbs and with normal goat serum for polyclonal antibodies (1 : IO). To enhance immunostaining for Tdt, sections were digested with DNAse 0.1% in Tris buffer for 2 hours and with 0.03% protease type XIV (Sigma Chemical CO, St Louis, MO) in PBS for 3 minutes before incubating with primacy antibody. For the peroxidase staining procedure, we used ABC Elite kits (Vector Laboratories, Burlingame, CA). We used 3-amino-9-ethylcarbaole as chromogen in developing the immunostaining. Slides were counterstained with Mayer's hematoxylin. To evaluate specificity of the antibodies, we used known positive and negative tissues as controls. Details of the immunostaining procedure have been described previously.12
Amplification of human DNA (HLA-DQa) and Epstein-Barr virus-specific sequences by polymerase chain reaction. The presence of human and viral DNA in mouse tissue was detected by polymerase chain reaction (PCR) using primers specific for DNA sequences of HLA-DQaI3 and Epstein-Barr virus (EBV) Bam W.14 DNA was prepared from fresh or frozen tissues and cells as described Specific positive and negative controls were used in every PCR assay. The amplified product was separated by electrophoresis in a 1.6% agarose gel. After staining with ethidium bromide, positive results signaling the presence of human and EBV DNA were detected as a 225-bp and 125-bp band, respectively.
Multiparameterflow cytometry.
Multiparameter flow cytometric analysis using two-color immunofluorescence staining techniques was performed on original leukemic blasts and on blast cell populations in cell suspensions from bone marrow and spleen of SCID mice to identify and characterize the human leukemia cells. Cells were purchased from Coulter Corp (Hialeah, FL), H-2K from Pharmingen (San Diego, CA), and Tdt from Supertechs (Bethesda, MD). All other antibodies were from Becton Dickinson Immunocytochemistry Systems (BDIS, San Jose, CA). After incubation for IO minutes at 4"C, the erythrocytes were lysed with N&CL for IO minutes and then washed twice with a PBS solution. The cells were resuspended, fixed with 1% paraformaldehyde, and analyzed by flow cytometry on a FAC Scan (BDIS) using Consort 30 or Lysis I1 software (BDIS). The leukemic cell population was gated based on cell size and rightangle light-scatter pattern. The result of each marker was expressed as the percent of positive cells in the gated blast population.
RESULTS AND DISCUSSION
Engraftment of leukemic cells and correlation with patient cell phenorype. Engraftment of childhood ALL in SCID mice has been reported by several groups.6-Lo Some of these results indicate a potential clinicallprognostic relevance for this Although a few anecdotal cases of successful engraftment of adult ALL-derived leukemic cells have been reported," our study is the first to analyze systematically the biologic differences between defined subcategories of untreated adult ALL with regard to their engraftment and dissemination in SCID mice. We focused on the association between the subtype of leukemia and organ involvement, For Blood, spleen, liver, and brain (lanes 5, 7, 8 , and 10) were negative for human DQa. Lane 11 is a negative control (mouse thymus lymphoma). A complete summary of experimental data is shown in Table 2 .
stability of the leukemic immunophenotype. time to disease development, and mice survival duration.
After transplanting blood-derived leukemic cells from I3 patients encompassing five subcategories of ALL a s defined by immunophenotype. karyotype. or both. we obtained engraftment with cells from 10 patients (76%) who represented a l l categories studied ( Table 1 ) . The engraftment was studied either at the time of terminal illness or at the time experiments were concluded. 7 to 8 months after transplantation. It was documented by the presence of DNA sequences specific for the human DQa gene. Tissue specificity was then evaluated by immunohistochemistry for reactivity with antibodies to human LCA (CD45). The ERV genome-specific Bam W DNA sequences indicative of ERV-associated Bcell proliferation" were detected in mouse tissues engrafted with cells from one patient. that was excluded from analysis.
Leukemic growth in all other cases was negative for the presence of EBV, indicating true leukemic engraftment. This was supported by cytochemical and immunophenotypic findings compatible with those of the original leukemia.
Engraftment of leukemic cells was documented for all phenotypes and karyotypes studied (Tables 1 and 2 ). Leukemia developed in mice engrafted with ALL cells from two of three diploid karyotype. two of three t( I I q23). two of two hyperdiploid. two of two T-cell. and two of three t(9:22). The shortest time to development of clinically evident disease was 49 days. and the longest was 238 days (Table 2) .
Minimal disease was detected at the end of the 7-to %month observation period in mice engrafted with diploid and Ph' subcategories. more frequently in those with the diploid karyotype. A diploid karyotype confers an average prognosis, whereas the t(9:22) karyotype is associated with the poorest prognosis.' We therefore expected the Philadelphia chromosome to be associated with aggressive growth in SClD animals. However. it is possible that Ph' ALL cells require species-specific human hematopoietic growth factors to grow in vivo. Recently. Estrov et a l i S reported a divergent proliferative response to granulocyte-macrophage colonystimulating factor in Ph' ALL cell lines. It is possible that supplementing recipients with myeloid growth factors could modify the growth of these cells in vivo. as has been seen with acute myeloid leukemia cells.'"
The number of patients in this study is too small to evaluate the prognostic value of the SClD engraftment model for patient outcome. Although the most rapid engraftment occurred with cells from patient no. 9. who had T-cell ALL resistant to induction therapy with vincristine. Adriamycin (Adria Laboratories. Columbus. OH). and dexamethasone,'" there was no consistent correlation between the engraftment or survival of mice and the clinical outcome or laboratory features of ALL cells injected ( Table I ) . We have used ALL cells from blood collected by pheresis. Since this procedure was used in patients with greater than 10.000 blast cells/pL at the time of cell collection. patient selection for our study may have been biased toward poorer-prognosis groups.2" This supposition seems to be supported by the long-term outcome. since only two of 13 patients (15%) are still alive. Studies in childhood ALL have indicated that a higher engraftment rate and a shorter time to development of overt leukemia in SClD mice are associated with more aggressive disease in children. Conversely. failure to engraft in SClD mice was associated with a subsequent long-term diseasefree survival.'"" The lack of correlation between engraftment and clinical outcome in this study might be explained by the fact that adult ALL is a higher-risk disease than childhood ALL. and our population sample was further biased by our selecting higher-risk patients who had elevated white blood cell counts.
Ptrttem of ledwrnic sl~rcud crnd pherlot!pe stcrhilih ir7 SClD micc~. Generally. organ involvement was similar to that seen in human disease: in a l l mice in which leukemic cells engrafted. bone marrow and spleen were infiltrated with human ALL cells. At necropsy. evidence of disease was observed in all I O cases that engrafted. Splenomegaly was noted in 10 (100%) and hepatomegaly in 7 (70%). A mediastinal mass was found in 4 (40%) and a n intraabdominal mass in 7 (70%); 4 mice groups showed extensive abdominal disease involving kidneys, ovaries, intestines, and pancreas. Involvement of nonhematopoietic tissues was most extensive in those with T-cell leukemias, followed by those with t(l lq23) and hyperdiploid varieties. The least extrahematopoietic involvement was associated with diploid disease (Table 2). These findings tended to correlate negatively with the survival of animals.
Immunohistochemistry with antibodies to B-cell (L26) and T-cell (UCHL-1) antigens and cytochemistry for Tdt identified leukemic cells consistent with the original phenotype (Fig l) . Infiltration of tissues with human cells was assessed by cell reactivity with antibodies to LCA (CD45) (Fig 2) . Such cells were detected in bone marrow and spleen of all 10 cases in which engraftment was also confirmed by the presence of human DNA-specific DQa sequences (Fig  3) . Brain involvement was observed in five cases, including two t( 1 lq23), two T-cell ALL, and one hyperdiploid. In all cases, there was meningeal infiltration; in two cases, it invaded the parenchyma, mimicking the pathophysiology of human ALL disease. In our adult patient population, meningeal leukemia is most frequently observed in B-and T-cell subtypes, but is also noted in other ALL subcategories. The lungs were involved in six cases, where leukemic cells infiltrated the alveolar septa and perivascular space and were also present intravenously (Fig 1, Table 2 ). LCA-positive cells were detected in all organs that were enlarged at necropsy, such as spleen, liver, mesentery, and mediastinum, except in three mice in which the large mediastinal mass was caused by mouse thymic tumor ( Table 2) . Tumors of the thymus are detected in about 10% of CB17-SCID mice aged 5 to 9 months. They appear to be spontaneous T-cell lymphomas of mouse origin and are highly invasive."
To establish the validity of the SCID model of human ALL, it is important to document that the leukemia engrafted in mice is representative of the original disease. The immunophenotype of leukemic cells infiltrating the murine spleen and bone marrow was studied in detail in four cases, each representing a distinctive subcategory of ALL. Using a series of MoAbs and flow cytometry, we found no significant changes in the expression of antigenic determinants during the prolonged period of cell growth in SCID mice (Table  3) . This finding suggests stability of the leukemic cells in a xenogeneic environment and the absence of phenotypic selection. This is consistent with our findings using leukemic cell linesI6 and those of others using adult and childhood ALL cell^.^.^ A complete karyotypic evaluation would be necessary to document whether clonal selectiodevolution, commonly observed with established cell lines in vitro, also takes place in vivo. The lack of ability of ALL cells, passaged through SCID mice, to grow as cell lines in vitro argues against such selection occurring in SCID mice.
Passage studies. The ultimate test of the biologic properties and malignant potential of leukemic cells is their behavior in vivo (ie, their proliferative rate and tissue invasiveness). Biologic heterogeneity is associated with differing prognoses and responsiveness to chemotherapeutic or biologic agents. Additionally, these properties evolve during the course of the disease. Such clonal evolution is due to genetic instability of the malignant cells and results in new clones emerging either under pressure by natural selection or by selection pressures of the chemotherapeutic agents used.
For the SCID model of human ALL to be useful in evaluating new therapeutic approaches, it is important to document reproducibility of engraftment of the disease in SCID. Leukemic cells from a patient with T-cell ALL (patient no. 9) were injected into two sets of SCID mice at different periods. The identical survival times of the engrafted animals (Table 4) , as well as identical tissue involvement, verified reproducibility of the model; the same verification occurred with myeloid cell linesI6 and primary AML (S.J., in preparation). To ascertain the extent to which biologic properties of leukemic cells remain the same when engrafted into SCID mice, we have passaged leukemic cells engrafted in spleen or bone marrow of SCID mice into a second set of animals, by injecting cells intravenously in numbers comparable to those contained in the primary leukemia inoculation. Using cells from six patients representing four different subtypes of leukemia (diploid, hyperdiploid, t(l lq23), and T-cell), we achieved engraftment with all subtypes and in 100% of the animals. Importantly, these animals' survival time was comparable to the survival time of those engrafted with primary cells (Table 4) , as was the extent of tissue invasion and the phenotype. In contrast to the extensive selection that occurs during establishment of in vitro cell lines, the environment of the SCID mice allowed manifestation of the intrinsic biologic properties of several subtypes of adult ALL. These data are in agreement with the reported experience in childhood ALL6-9 and with our recent data on phenotypic and biologic stability of leukemic populations derived from adults with relapsed ALL (P.P., personal communication, February 1995) and acute myeloid leukemia (S.J., in preparation). With a similar number of cells injected into an identical lot of animals during the same period, the variations in the time from engraftment to overt leukemia can be explained by the different biologic properties of the inoculated cells.
Comparison of results on frequency and mode of engraftment from different laboratories and different periods in the same laboratory is hampered by difficulties in standardizing such assays, even when using identical strains of SCID mice. When the natural-killer cell and macrophage components of the immune systems are intact, the frequency of engraftment is bound to vary with the presence of subclinical infections known to influence greatly the rejection of xenografts' (also M.B., personal observations, August 1994) and perhaps also with the age of the animals.
In this communication, we report successful engraftment of leukemic cells from adult ALL in SCID mice and describe the in vivo behavior of these cells in primary and secondary recipients. ALL is a heterogenous group of diseases that have differing phenotypes, genotypes, and, most importantly, outcomes after therapeutic intervention." The basis for such differences is not known and may reside in the intrinsic biologic properties of individual leukemic populat i o n~.~~ Development of in vivo experimental models would allow evaluation under well-defined conditions of both biologic differences and differences in response to therapeutic agents, ultimately leading to more specific treatment regimens for each subcategory of the disease.
In childhood ALL, engraftment of leukemic cells in SCID mice established a new way to study this disease and suggested its potential clinical usefulness and prognostic relevance. Our study is the first to document the relationship between the phenotypic-genotypic characteristics of adult ALL cells and their engraftment and dissemination in SCID animals. The association of engraftment in SCID mice and response to therapy was one of the primary questions in our study. The reports by Uckun et ala"' and Kamel-Reid et al' indicated that in children, lack of engraftment was associated with long-term disease-free survival, whereas leukemic cells from patients who had an early relapse engrafted rapidly and disseminated aggressively. Our results showed a higher frequency of engraftment that, in itself, was not related to remission induction or survival (Table 1) . This model may reflect the more aggressive nature of adult ALL as compared with childhood ALL. Engraftment occurred from each of five subcategories of ALL. Cells with the l l q abnormality, hyperdiploid cells, and T cells seemed to engraft most readily, whereas diploid and Ph+ cells engrafted less frequently and disseminated less extensively. The persistence of leukemic cells without signs of disease in some categories of ALL suggests that this may also be a suitable model of minimal residual disease. Such a model is clearly different from models of animal leukemias that have rapid proliferation of cells and short recipient survival durations.
In summary, we have developed a SCID mouse model for human adult ALL that will be used (1) to study the biology and pathophysiology of adult ALL and ( 2 ) to investigate various therapeutic approaches (chemotherapy, biologic immunomodulation, cell-gene targeted therapy, and treatment of minimal residual disease) in each of the adult ALL subsets.
